Showing 3201-3210 of 4063 results for "".
- B+L Shares Dry Eye Survey Results and Launches Awareness Campaignhttps://modernod.com/news/bl-shares-dry-eye-survey-results-and-launches-awareness-campaign/2482346/Bausch + Lomb shared results from its 'State of Dry Eye' survey, which aimed to explore dry eye understanding and experiences among adults in the US. The research was conducted online by The Harris Poll on behalf of Bausch + Lomb among 2,003 U.S. adults 18 years o
- Alcon Completes Acquisition of Belkin Visionhttps://modernod.com/news/alcon-completes-acquisition-of-belkin-vision/2482338/Alcon announced the closing of its acquisition of Belkin Vision, which was initially reported in May 2024. The acquisition involved a total upfront
- Karen Petrou Appointed Board Chair of the Foundation Fighting Blindnesshttps://modernod.com/news/karen-petrou-appointed-board-chair-of-the-foundation-fighting-blindness/2482334/The Foundation Fighting Blindness announced the appointment of Karen Petrou as Board Chair, effective July 1, 2024. Petrou succeeds David Brint, who is retiring after 8 years of service. Ms. Petrou’s becomes the third person to hold the position in the Foundation&rs
- FDA Grants DeNovo Classification to Balance Ophthalmics' FYSX Ocular Pressure Adjusting Pumphttps://modernod.com/news/fda-grants-denovo-classification-to-balance-ophthalmics-fysxtm-ocular-pressure-adjusting-pump/2482333/Balance Ophthalmics announced that the FDA has granted DeNovo Classification of the FYSX Ocular Pressure Adjusting Pump, a new category of treatment for patients with normal tension glaucoma (NTG) and open-angle glaucoma (OAG) with IOP ≤ 21 mmHg. “The FDA classif
- Oertli Instrumente Wins the Swiss Medtech Awardhttps://modernod.com/news/oertli-instrumente-wins-the-swiss-medtech-award/2482318/Oertli Instrumente was awarded the Swiss Medtech Award at the Swiss Medtech Day, which came with an prize of CHF 75,000 ($83,600). The Swiss Medtech Award, established in 2018, recognizes outstanding achievements in the Swiss medical technology industry. Th
- Nidek Launches the RS-1 Glauvas Optical Coherence Tomography Devicehttps://modernod.com/news/nidek-launches-the-rs-1-glauvas-optical-coherence-tomography/2482304/Nidek has launched the RS-1 Glauvas Optical Coherence Tomography (OCT). The RS-1 Glauvas has up to 250kHz scan speed, wide and deep area imaging, operability, and deep learning-based analytics. The incorporation of 250,000 A-scans/s accelerates the workflow by reducing capture
- Haag-Streit Launches 3D Imaging Option for the Imaging Module 910https://modernod.com/news/haag-streit-launches-3d-imaging-option-for-the-imaging-module-910/2482281/Haag-Streit announced the launch of the Imaging Module 910 3D. "To-date, ophthalmologists have been able to document slit lamp images, but only in 2D. The images presented in two dimensions lack depth, which limits the comprehensive visualization of the observed content. By enhanci
- Humonix Biosciences Appoints Karen Torrejon, PhD, as New CEOhttps://modernod.com/news/humonix-biosciences-appoints-karen-torrejon-phd-as-new-ceo/2482275/Humonix Biosciences announced the appointment of Karen Torrejon, PhD, as the new Chief Executive Officer. Dr. Torrejon, who originally founded the company in 2014, will now be leading the company as it transitions into a broader, science-driven platform. Humonix’s platform has bee
- RevOpsis Names Emmett Cunningham, MD, PhD, to Strategic Advisory Boardhttps://modernod.com/news/revopsis-names-emmett-cunningham-md-phd-to-strategic-advisory-board/2482273/RevOpsis Therapeutics announced the appointment of Emmett Cunningham, MD, PhD, to its Strategic Advisory Board (SAB) and as a private investor. Dr. Cunningham brings more than 20 years of experience as a full-time entrepreneur and investor to his new role with RevOpsis. Dr. Cunning
- AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Wet AMDhttps://modernod.com/news/asclepix-therapeutics-completes-enrollment-in-discover-trial-for-wet-amd/2482271/AsclepiX Therapeutics announced the completion of enrollment into the DISCOVER trial (NCT05859776) evaluating the safety and tolerability of three dose strengths of AXT107 (gersizangitide) for wet AMD. In the trial, 15 patients will receive either 125 µg (n=3), 250 &micr